Changes in magnetic resonance mammography due to hormone replacement therapy

Breast Cancer Research

Volumn 6, Issue 3, 2004, Pages

  Pfleiderer, Stefan O R ^a   Sachse, Steffen ^a   Sauner, Dieter ^a   Marx, Christiane ^a   Malich, Ansgar ^a   Wurdinger, Susanne ^a   Kaiser, Werner A ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Breast; Breast cancer; Ductal carcinoma in situ; Hormone replacement therapy; Magnetic resonance imaging

Indexed keywords

ADULT; ARTICLE; COMPARATIVE STUDY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; GRADIENT ECHO SEQUENCE; HORMONE SUBSTITUTION; HUMAN; IMAGE ANALYSIS; KINETICS; MAGNETIC RESONANCE MAMMOGRAPHY; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL PARAMETERS; POSTMENOPAUSE; REPRODUCIBILITY; THICKNESS; TREATMENT WITHDRAWAL; TURBO SPIN ECHO SEQUENCE; ADIPOSE TISSUE; BREAST; CONNECTIVE TISSUE; DRUG EFFECT; FOLLOW UP; HISTOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY;

CONTRAST MEDIUM;

ADIPOSE TISSUE; ADULT; BREAST; CONNECTIVE TISSUE; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; POSTMENOPAUSE; RETROSPECTIVE STUDIES; WITHHOLDING TREATMENT;

EID: 3142705682     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr779     Document Type: Article

References (31)

1. Gibaldi M: Prevention and treatment of osteoporosis: does the future belong to hormone replacement therapy. J Clin Pharmacol. 1997, 37: 1087-1099.
2. Lindsay R: Hormone replacement therapy for prevention and treatment of osteoporosis. Am J Med. 1993, 95: 37S-39S.
3. Stampfer M, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurse's Health Study. N Engl J Med. 1991, 325: 1758-1766.
4. Rich-Edwards JW, Manson JE, Hennekens CH, Buring JE: The primary prevention of coronary heart disease in women. N Engl J Med. 1995, 332: 1758-1766. 10.1056/NEJM199506293322607.
5. Grimes DA, Lobo RA: Perspectives on the Women's Health Initiative trial of hormonal replacement therapy. Obstet Gynecol. 2002, 100: 1344-1353. 10.1016/S0029-7844(02)02503-6.
6. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, Marchbanks PA, Norman SA, Weiss LK, Ursin G, Berlin JA, Burkman RT, Deapen D, Folger SG, McDonald JA, Simon MS, Strom BL, Wingo PA, Spirtas R: Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. Cancer. 2002, 95: 2455-2465. 10.1002/cncr.10984.
7. Persson I, Thurfjell E, Bergstrom R, Holmberg L: Hormone replacement therapy and the risk of breast cancer. Nested case-control study in a cohort of Swedish women attending mammography screening. Int J Cancer. 1997, 72: 758-761. 10.1002/(SICI)1097-0215(19970904)72:5<758::AID-IJC9>3.3.CO;2-2.
8. Harvey JA, Pinkerton JV, Herman CR: Short-term cessation of hormone replacement therapy and improvement in mammographic specificity. J Natl Cancer Inst. 1997, 89: 1623-1625. 10.1093/jnci/89.21.1623.
9. Vachon CM, Sellers TA, Vierkant RA, Wu FF, Brandt KR: Case-control study of increased mammographic breast density response to hormone replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002, 11: 1382-1388.
10. Litherland JC, Stallard S, Hole D, Cordiner C: The effect of hormone replacement therapy on the sensitivity of screening mammograms. Clin Radiol. 1999, 54: 285-288. 10.1016/S0009-9260(99)90555-X.
11. Banks E: Hormone replacement therapy and the sensitivity and specificity of breast cancer screening. a review. J Med Screen. 2001, 8: 29-34. 10.1136/jms.8.1.29.
12. Marugg RC, van der Mooren MJ, Hendriks JH, Holland R, Ruijs SH: Mammographic changes in postmenopausal women on Hormone replacement therapy. Eur Radiol. 1997, 7: 749-755.
13. Ozdemir A, Konus O, Nas T, Erbas G, Cosar S, Isik S: Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynecol Obstet. 1999, 67: 23-32. 10.1016/S0020-7292(99)00102-2.
14. Germer U, Tetzlaff A, Geipel A, Diedrich K, Gembruch U: Strong impact of estrogen environment on Doppler variables used for differentiation between benign and malignant breast lesions. Ultrasound Obstet Gynecol. 2002, 19: 380-385. 10.1046/j.1469-0705.2002.00675.x.
15. Nelson TR, Pretorius DH, Schiffer LM: Menstrual variation of normal breast NMR relaxation parameters. J Comput Assist Tomogr. 1985, 9: 875-879.
16. Martin B, El Yousef SJ: Transverse relaxation time values in MR imaging of normal breast during menstrual cycle. J Comput Assist Tomogr. 1986, 10: 924-927.
17. Rieber A, Nüssle K, Merckle E, Kreienberg R, Tomczak R, Brambs HJ: MR mammography. influence of menstrual cycle on the dynamic contrast enhancement of fibrocystic disease. Eur Radiol. 1999, 9: 1107-1112. 10.1007/s003300050800.
18. Müller-Schimpfle M, Ohmenhausen K, Stoll P, Dietz K, Claussen CD: Menstrual cycle and age. influence on parenchymal contrast medium enhancement in MR imaging of the breast. Radiology. 1997, 203: 145-149.
19. Heywang-Köbrunner SH, Viehweg P, Heinig A, Küchler C: Contrast-enhanced MR imaging of the breast. accuracy, value, controversies, solutions. Eur J Radiol. 1997, 24: 94-108. 10.1016/S0720-048X(96)01142-4.
20. Hussain Z, Roberts N, Whitehouse GH, Garcia-Finana M, Percy D: Estimation of breast volume and its variation during the menstrual cycle using MRI and stereology. Br J Radiol. 1999, 72: 236-245.
21. Reichenbach JR, Przetak C, Klinger G, Kaiser WA: Assessment of breast tissue changes on hormonal replacement therapy using MRI. a pilot study. J Comput Assist Tomogr. 1999, 23: 407-413. 10.1097/00004728-199905000-00015.
22. Kaiser WA, Zeitler E: MR-imaging of the breast: fast imaging sequences with and without Gd-DTPA. Radiology. 1989, 170: 681-686.
23. Graham SJ, Stanchev PL, Lloyd-Smith CO, Bronskill MJ, Plewes DB: Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging. 1995, 5: 695-701.
24. Ottesen GL, Graversen HP, Blichert-Toft M, Zedeler K, Andersen JA: Lobular carcinoma in situ of the female breast. Am J Surg Pathol. 1993, 17: 14-21.
25. Neubauer H, Li M, Kuehne-Heid R, Schneider A, Kaiser WA: High grade and non-high grade ductal carcinoma in situ on dynamic MR mammography. characteristic findings for signal increase and morphological pattern of enhancement. Br J Radiol. 2003, 76: 3-12. 10.1259/bjr/14883856.
26. Taylor JS, Tofts PS, Port R, Evelhoch JL, Knopp M, Reddick WE, Runge VM, Mayr N: MR imaging of tumor microcirculation. promise for the new millennium. J Magn Reson Imaging. 1999, 10: 903-907. 10.1002/(SICI)1522-2586(199912)10:6<903::AID-JMRI1>3.0.CO;2-A.
27. Pike MC, Spicer DV, Dahmoush L, Press MF: Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993, 15: 17-35.
28. Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC: Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk. J Natl Cancer Inst. 1994, 86: 431-436.
29. Fowler PA, Casey CE, Cameron GG, Foster MA, Knight CH: Cyclic changes in composition and volume of the breast during the menstrual cycle, measured by magnetic resonance imaging. Br J Obstet Gynecol. 1990, 97: 595-602.
30. Kuhl CK, Bieling HB, Gieseke J, Kreft BP, Sommer T, Lutterbey G, Schild HH: Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast. Normal contrast medium enhancement and cyclical-phase dependency. Radiology. 1997, 203: 137-144.
31. Bogin L, Degani H: Hormonal regulation in orthotopic MCF7 human breast cancer. Cancer Res. 2002, 62: 1948-1951.